

Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi -110 033
Telefax : + 91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



Ref: IIL/SE/2024/0502/1
Dated: February 05, 2024

The Manager

Listing Compliance Department BSE Limited (Through BSE Listing Centre) Scrip Code: 532851	Listing Compliance Department National Stock Exchange of India Limited (Through NEAPS) Symbol: INSECTICID
--	--

Dear Sir/Madam,

Re: Outcome of the Board Meeting

This has reference to our letter no. IIL/SE/2023/2912/1 dated December 29, 2023

The Board of Directors at the meeting held today, i.e February 05, 2024 *inter alia* considered and approved the following:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2023 along with Limited Review Report of M/s S S Kothari Mehta & Company and M/s Devesh Parekh & Co., Joint Statutory Auditors of the Company on the Financial Statements. The Financial Results were reviewed and recommended by the Audit Committee. Accordingly, we enclosed the following:
 - Un-audited Standalone and Consolidated Financial Statements of the Company for the third quarter and nine months ended December 31, 2023.
 - Limited Review Report of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2024.

This above said results is also available on the website of the Company at <https://www.insecticidesindia.com/investors-desk/>

2. Appointment of Director(s):

- a) Appointment of Mr. Shyam Lal Bansal (DIN: 02910086) as an Additional Independent Director w.e.f. February 05, 2024 for a period of five years, not liable to retire by rotation, subject to approval of the shareholders.
- b) Appointment of Mr. Supratim Bandyopadhyay (DIN: 03558215) as an Additional Independent Director w.e.f. February 05, 2024 for a period of five years, not liable to retire by rotation, subject to approval of the shareholders.

The requisite details of appointment(s) are given under **Annexure - A** enclosed to this letter.

We hereby confirm that Mr. Shyam Lal Bansal (DIN: 02910086) and Mr. Supratim Bandyopadhyay (DIN: 03558215) are not debarred from holding the office of director by virtue of any SEBI order or any other such authority”

3. Retirement of Director

The Board took note of Mr. S. Jayaraman's retirement, which will take effect on February 08, 2024, marking the completion of his second term. S. Jayaraman served as an independent director for consecutive two term, his present term of five years spanning from February 09, 2019 to February 08, 2024.

The Board meeting commenced at 03:00 PM and concluded at 04:45 PM

You are requested to kindly take on records.

Thanking You,
For Insecticides India Limited

Sandee
p Kumar

Digitally signed by
Sandeep Kumar
Date: 2024.02.05
16:42:02 +05'30'

Sandeep Kumar
(Company Secretary & CCO)

Encl: As above

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(₹ In Lacs, except EPS)

k	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2023 (Unaudited)	30-09-2023 (Unaudited)	31-12-2022 (Unaudited)	31-12-2023 (Unaudited)	31-12-2022 (Unaudited)	31-03-2023 (Audited)
I	Revenue from operations	35,794.22	69,598.78	35,653.24	1,69,388.34	1,49,943.13	1,80,132.85
II	Other Income	123.49	(17.37)	37.42	494.85	85.17	126.39
III	Total Income (I+II)	35,917.71	69,581.41	35,690.66	1,69,883.19	1,50,028.30	1,80,259.24
IV	Expenses						
	(a) Cost of materials consumed	26,041.79	39,166.29	20,441.37	1,06,209.09	1,07,633.48	1,39,946.52
	(b) Purchase of Stock-in-Trade	3,941.55	6,750.56	2,346.65	15,119.60	8,857.33	11,212.48
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,984.48)	6,327.98	4,029.77	6,608.08	(4,371.47)	(12,596.77)
	(d) Employee benefits expense	2,774.56	3,413.98	2,292.18	9,152.99	7,672.48	9,838.05
	(e) Finance costs	278.68	286.08	483.77	881.40	898.54	1,345.10
	(f) Depreciation and amortization expense	741.81	735.12	643.22	2,165.00	1,945.46	2,610.18
	(g) Other expenses	5,419.67	5,711.50	4,211.96	16,904.08	15,129.04	19,542.97
	Total expenses	34,213.58	62,391.51	34,448.92	1,57,040.24	1,37,764.86	1,71,898.53
V	Profit before tax (III-IV)	1,704.13	7,189.90	1,241.74	12,842.95	12,263.44	8,360.71
VI	Tax Expense						
	(1) Current Tax	542.34	1,831.09	305.27	3,445.44	3,133.84	2,082.85
	(2) Deferred Tax	(65.58)	34.66	3.08	(57.12)	(69.97)	(20.89)
	Total Tax Expense	476.76	1,865.75	308.35	3,388.32	3,063.87	2,061.96
VII	Profit / (loss) for the period (V-VI)	1,227.37	5,324.15	933.39	9,454.63	9,199.57	6,298.75
VIII	Other comprehensive income						
A	Items that will not be reclassified to profit or loss						
	(i) Changes in fair value of FVTOCI equity instruments	33.72	(139.82)	(48.69)	109.73	163.76	111.46
	(ii) Remeasurement of net defined benefit plans	(20.00)	(20.00)	(7.50)	(60.00)	(22.50)	(75.76)
	(iii) Income tax relating to these items	(2.82)	37.60	13.23	(10.46)	(32.49)	(6.90)
	Other comprehensive income for the period (net of tax)	10.90	(122.22)	(42.96)	39.27	108.77	28.80
IX	Total comprehensive income for the period (VII+VIII)	1,238.27	5,201.93	890.43	9,493.90	9,308.34	6,327.55
	Paid up equity share capital (Face value ₹ 10/- each)	2,959.78	2,959.78	2,959.78	2,959.78	2,959.78	2,959.78
	Earnings per share (of ₹ 10 each):						
	(a) Basic	4.14	17.99	3.15	31.94	31.08	21.28
	(b) Diluted	4.14	17.99	3.15	31.94	31.08	21.28
	(Note: EPS for respective quarters are not annualized)						

Notes:

- The above Unaudited Standalone Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 05, 2024. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- The above Standalone Unaudited Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- The Company's wholly owned subsidiary IIL Biologicals Limited has successfully completed the rights issue of Equity Shares of INR 82.00 Lakhs on 25th September 2023.
- During the period ended June 30, 2023 the the wholly-owned subsidiary was incorporated on May 01, 2023 namely "IIL Overseas DMCC" (Dubai) by the Company. The wholly-owned subsidiary shall carry on the business of trading of Insecticides, Agricultural & Veterinary Pesticides Products.
- Previous period figures have been re-grouped and/ or re-arranged wherever necessary to make their classification comparable with the current period.

Place: Delhi

Date: February 05, 2024



For and on behalf of the Board

Rajesh Kumar Aggarwal
Managing Director

DIN : 00576872

**S S KOTHARI MEHTA
& COMPANY**

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi - 110020

DEVESH PAREKH & CO.

Chartered Accountants
675, Aggarwal Cyber Plaza-2,
Netaji Subhash Place, Pitampura, Delhi-110034

Independent Auditor's Review Report on the Standalone Unaudited Quarterly and Year to Date Financial Results of the Insecticides (India) Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
**The Board of Directors of
Insecticides (India) Limited
New Delhi**

Review Report on the Standalone Unaudited Financial Results

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Insecticides (India) Limited** ("the Company") for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, as amended (the "Listing Regulations").
2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.



**S S KOTHARI MEHTA
& COMPANY**


Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi -110020

DEVESH PAREKH & CO.

Chartered Accountants
675, Aggarwal Cyber Plaza-2,
Netaji Subhash Place, Pitampura, Delhi-110034

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable Indian Accounting Standards (Ind-AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S S Kothari Mehta & Co.**
Chartered Accountants
Firm's registration number: 000756N



Vijay Kumar
Partner
Membership number: 092671
UDIN: 24092671BKFBNB7658



Place: New Delhi
Date: 5th February, 2024

For **Devesh Parekh & Co.**
Chartered Accountants
Firm's registration number: 013338N



Devesh Parekh
Partner
Membership number: 092160
UDIN: 24092160BKDFQW2342

Place: Delhi
Date: 5th February, 2024

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(₹ In Lacs, except EPS)

Sl No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2023 (Unaudited)	30-09-2023 (Unaudited)	31-12-2022 (Unaudited)	31-12-2023 (Unaudited)	31-12-2022 (Unaudited)	31-03-2023 (Audited)
I	Revenue from operations	35,794.22	69,598.78	35,653.24	1,69,388.34	1,49,943.13	1,80,132.85
II	Other Income	121.93	(17.37)	37.42	493.29	85.17	126.39
III	Total Income (I+II)	35,916.15	69,581.41	35,690.66	1,69,881.63	1,50,028.30	1,80,259.24
IV	Expenses						
	(a) Cost of materials consumed	26,041.79	39,166.29	20,441.37	1,06,209.09	1,07,633.48	1,39,946.52
	(b) Purchase of Stock-in-Trade	3,941.55	6,750.56	2,346.65	15,119.60	8,857.33	11,212.48
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,984.48)	6,327.98	4,029.77	6,608.08	(4,371.47)	(12,596.77)
	(d) Employee benefits expense	2,774.56	3,413.98	2,292.18	9,152.99	7,672.48	9,838.05
	(e) Finance costs	278.68	286.08	483.77	881.40	898.54	1,345.10
	(f) Depreciation and amortization expense	741.81	735.12	643.22	2,165.00	1,945.46	2,610.18
	(g) Other expenses	5,419.71	5,746.68	4,217.56	16,939.36	15,134.84	19,543.97
	Total expenses	34,213.62	62,426.69	34,454.52	1,57,075.52	1,37,770.66	1,71,899.53
V	Profit before tax, exceptional items and share of net profit of investment accounted for using equity method (III-IV)	1,702.53	7,154.72	1,236.14	12,806.11	12,257.64	8,359.71
VI	Share of net profit of joint venture accounted for using the equity method	4.92	20.32	8.77	36.34	56.99	23.20
VII	Profit / (loss) Before Tax (V+VI)	1,707.45	7,175.04	1,244.91	12,842.45	12,314.63	8,382.91
VIII	Tax Expense						
	(1) Current Tax	542.34	1,831.09	305.27	3,445.44	3,133.84	2,082.85
	(2) Deferred Tax	(65.58)	28.63	3.08	(63.15)	(69.97)	(21.06)
	Total Tax Expense	476.76	1,859.72	308.35	3,382.29	3,063.87	2,061.79
IX	Profit / (loss) for the period (VII-VIII)	1,230.69	5,315.32	936.56	9,460.16	9,250.76	6,321.12
X	Other comprehensive income						
A	Items that will not be reclassified to profit or loss						
	(i) Changes in fair value of FVTOCI equity instruments	33.72	(139.82)	(48.69)	109.73	163.76	111.46
	(ii) Remeasurement of net defined benefit plans	(20.00)	(20.00)	(7.50)	(60.00)	(22.50)	(75.76)
	(iii) Share of Other comprehensive income of joint venture accounted	(0.23)	0.46	0.89	(0.69)	2.45	4.15
	(iv) Income tax relating to these items	(2.77)	37.49	13.01	(10.29)	(33.10)	(7.94)
	Other comprehensive income for the period (net of tax)	10.72	(121.87)	(42.29)	38.75	110.61	31.91
XI	Total comprehensive income for the period (IX+X)	1,241.41	5,193.45	894.27	9,498.91	9,361.37	6,353.03
	Paid up equity share capital (Face value ₹ 10/- each)	2,959.78	2,959.78	2,959.78	2,959.78	2,959.78	2,959.78
	Earnings per share (of ₹ 10 each) (not annualised):						
	(a) Basic	4.16	17.95	3.16	31.96	31.25	21.36
	(b) Diluted	4.16	17.95	3.16	31.96	31.25	21.36

Notes:

- The above Unaudited Consolidated Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 05, 2024. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- The above Consolidated Unaudited Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- The Group is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- The Company's wholly owned subsidiary IIL Biologicals Limited has successfully completed the rights issue of Equity Shares of INR 82.00 Lakhs on 25th September 2023.
- During the period ended June 30, 2023 the wholly-owned subsidiary was incorporated on May 01, 2023 namely "IIL Overseas DMCC" (Dubai) by the Group. The wholly-owned subsidiary shall carry on the business of trading of Insecticides, Agricultural & Veterinary Pesticides Products.
- Previous period figures have been re-grouped and/ or re-arranged wherever necessary to make their classification comparable with the current period.

Place: Delhi
Date: February 05, 2024



For and on behalf of the Board

Rajesh Kumar Aggarwal
Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

**SS KOTHARI MEHTA
& COMPANY**

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi - 110020

DEVESH PAREKH & CO.

Chartered Accountants
675, Aggarwal Cyber Plaza-2,
Netaji Subhash Place, Pitampura, Delhi-110034

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Insecticides (India) Limited
New Delhi

Review Report on the Unaudited Consolidated Financial Results

1. We have reviewed the accompanying statement of Unaudited consolidated financial results of **Insecticides (India) Limited** ("Parent's or Company"), its subsidiaries and its jointly controlled entity for the quarter ended December 31, 2023 and year to date results for the period from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Parent's pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

Subsidiary

IIL Biologicals Limited
IIL Overseas DMCC (Dubai)

Joint Venture

OAT & IIL India Laboratories Private Limited



**SS KOTHARI MEHTA
& COMPANY**

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi -110020

DEVESH PAREKH & CO.

Chartered Accountants
675, Aggarwal Cyber Plaza 2,
Netaji Subhash Place, Pitampura, Delhi 110034

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the other matters referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


6. Other Matters:

- a) The accompanying unaudited consolidated financial results includes the unaudited financial result of one subsidiary, which reflect total revenue of Rs. Nil and Rs Nil, (total net profit/ (Loss) after tax of Rs. (-) 1.83 Lacs and Rs. (-) 31.04 Lacs and total comprehensive income of Rs. (-) 1.82 Lacs and Rs. (-) 31.04 Lacs for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023 respectively, which have been reviewed by one of the joint auditor individually.
- b) In respect of one foreign subsidiary incorporated during the period ended Dec 31,2023, which has not commenced its operation. Therefore the accompanying statement does not include financial results of this entity.
- c) The accompanying unaudited consolidated financial results also include the Group's share of net profit after tax of Rs 4.92 Lacs and Rs. 36.34 Lacs and total comprehensive income of Rs. 4.74 Lacs and Rs. 35.82 Lacs for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023 respectively as considered in the unaudited consolidated financial results, in respect of one joint ventures, based on their financial results which have not been reviewed by us. These unaudited consolidated financial results have been furnished to us by the Board of directors. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary & joint venture is based solely on such unreviewed/unaudited consolidated financial results. According to the information and explanations given to us by the Management, these financial results are not material to the parent.

Our conclusion on the statement is not modified in respect of the above matters.

For S S Kothari Mehta & Co.

Chartered Accountants
Firm's registration number: 300736


Vijay Kumar

Partner

Membership number: 092671

UDIN: 24092671BKFBNC6428

Place: New Delhi

Date: 5th February, 2024



For Devesh Parekh & Co.

Chartered Accountants
Firm's registration number: 013338N


Devesh Parekh

Partner

Membership number: 092160

UDIN: 24092160BKDFQV5444



Place: Delhi

Date: 5th February, 2024



Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi -110 033
Telefax : + 91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



Annexure - A

Details of appointment as required under Regulation 30(6) read with Para A (7) of Part A of Schedule II to the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

S.No.	Particulars	Description
1.	Name and DIN	Mr. Shyam Lal Bansal DIN: 02910086
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
3.	Date of appointment/cessation (as applicable)	February 05, 2024
4.	Term of appointment	For the period of 5 year, not liable to retire by rotation
5.	Brief profile (in case of appointment);	<p>Mr. Shyam Lal Bansal is a seasoned and accomplished banker with a distinguished career spanning more than four decades during which he handled a wide range of subjects pertaining to commercial banks in various high level capacities culminating as the Chairman & Managing Director of Oriental Bank of Commerce.</p> <p>Mr. Bansal is an alumni of Shri Ram College of Commerce, a Masters in Commerce and is a certified associate of the Indian Institute of Bankers. He started his career as a probationary officer in Union Bank of India and went on to have an illustrious professional innings spanning over 39 years in Banking Industry with Union Bank of India and Oriental Bank of Commerce. During his banking carrier with Union Bank, he headed various branches, regions and Zones and promoted to the position of General Manager in 2007. In April 2010 he took over as Executive Director of United Bank of India and in March 2012 he took over as Chairman and Managing Director of Oriental Bank of Commerce. He earlier held</p>

		Directorships at Canara HSBC Oriental Bank of Commerce Life Insurance Co Ltd and Oriental Insurance Co Ltd.
6.	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Shyam Lal Bansal is not related to any of the Director or KMP of the Company

Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi -110 033
Telefax : + 91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



S.No.	Particulars	Description
1.	Name and DIN	Mr. Supratim Bandyopadhyay DIN: 03558215
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
3.	Date of appointment/cessation (as applicable)	February 05, 2024
4.	Term of appointment	For the period of 5 year, liable to retire by rotation
5.	Brief profile (in case of appointment);	<p>Mr Supratim Bandyopadhyay, a Member of the Institute of Chartered Accountant, has vast experience in the field of Insurance, Finance, Investments and Debt operations. He is currently Chairman of a Consultative Committee on Investment for Insurance Companies, Board member of Aditya Birla Sunlife AMC and Canara HSBC Life Insurance Co Ltd.</p> <p>Mr. Bandyopadhyay earlier served as Chairman of Pension Fund Regulatory and Development Authority (PFRDA) for a period of three years from January 2020 to January 2023 and prior to this he was the Whole Time Member (Finance) of PFRDA for two years. During his tenure with PFRDA, the AUM of PFRDA increased almost 4 folds to ₹9 trillion. He held the position of Managing Director & Chief Executive Officer at LIC Pension Fund managing entire operations of LIC Pension Fund from April 14- Jan 18. Before LIC Pension Fund, he also served Life Insurance Corporation of India (LIC), the largest Insurance Company of India for a period of more than three and half decades. During his tenure at LIC, he worked in various capacities heading two large divisions apart from being Chief (Investment)& Executive Director (Investment).</p>

6.	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Supratim Bandyopadhyay is not related to any of the Director or KMP of the Company